These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10211782)

  • 1. Milestones in the development of Lym-1 therapy.
    DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
    Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
    J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
    Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
    Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
    DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
    Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
    Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.
    DeNardo SJ; Kroger LA; MacKenzie MR; Mirick GR; Shen S; DeNardo GL
    Cancer Biother Radiopharm; 1998 Feb; 13(1):1-12. PubMed ID: 10850337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
    DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
    Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
    Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR
    Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
    O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Carr CE; Mirick GR; DeNardo SJ
    J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
    DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ
    Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.
    DeNardo SJ; DeNardo GL; O'Grady LF; Hu E; Sytsma VM; Mills SL; Levy NB; Macey DJ; Miller CH; Epstein AL
    Int J Cancer Suppl; 1988; 3():96-101. PubMed ID: 3209308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
    O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
    DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A
    Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
    DeNardo SJ; DeNardo GL; Kukis DL; Shen S; Kroger LA; DeNardo DA; Goldstein DS; Mirick GR; Salako Q; Mausner LF; Srivastava SC; Meares CF
    J Nucl Med; 1999 Feb; 40(2):302-10. PubMed ID: 10025839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; Lamborn KR; Goldstein DS; Kroger LA; DeNardo SJ
    Cancer; 1997 Dec; 80(12 Suppl):2706-11. PubMed ID: 9406728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
    Kuzel T; Rosen ST; Zimmer AM; Silverstein EA; Spies S; Saletan SL; Norvitch ME; Birkhofer M; Shochat D; LoBuglio AF
    Cancer Biother; 1993; 8(1):3-16. PubMed ID: 7812346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.